Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer-Reference-Cited by-同舟云学术

Co-targeting RANK pathway treats and prevents acquired resistance to CDK4/6 inhibitors in luminal breast cancer

Published:2023-08 Issue:8 Volume:4 Page:101120
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Gomes Inês,Gallego-Paez Lina M.,Jiménez Maria,Santamaria Patricia G.,Mansinho André,Sousa Rita,Abreu Catarina,Suárez Eva González,Costa Luis,Casimiro Sandra^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference54 articles.

1. Differences in breast cancer survival by molecular subtypes in the United States;Howlader;Cancer Epidemiol. Biomarkers Prev.,2018

2. CDK4/6 inhibition in breast cancer: current practice and future directions;Pernas;Ther. Adv. Med. Oncol.,2018

3. Targeting CDK4 and CDK6 in cancer;Goel;Nat. Rev. Cancer,2022

4. RANK is essential for osteoclast and lymph node development;Dougall;Genes Dev.,1999

5. The roadmap of RANKL/RANK pathway in cancer;Casimiro;Cells,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy;Cureus;2024-06-28

2. Traditional Chinese medicine polysaccharide in nano-drug delivery systems: Current progress and future perspectives;Biomedicine & Pharmacotherapy;2024-04

3. Centrosomes and associated proteins in pathogenesis and treatment of breast cancer;Frontiers in Oncology;2024-03-28

4. The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer;Cancers;2023-10-02